Erlotinib
- PDF / 141,762 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 77 Downloads / 163 Views
1
Erlotinib Various toxicities: 3 case reports Three women, who had no history of hirsutism, hypertrichosis, or endocrine or paraneoplastic disorders, developed hair disorders during treatment with erlotinib monotherapy [dosage not stated] after first- or second-line chemotherapy had failed to control their lung cancer. Two of the women also developed other features of epidermal growth factor receptor (EGFR) inhibition. A 74-year-old woman began receiving erlotinib and, 6 weeks later, she gradually developed curly, elongated eyelashes bilaterally and long pigmented vellous hair over her entire face, predominantly on her lip and malar areas. Erlotinib was continued and she was offered the option of laser hair removal. A 60-year-old woman began receiving erlotinib and, 5 weeks later, she developed facial hypertrichosis and trichomegaly of her eyebrows and eyelashes. In addition, she developed a classical acneiform eruption on her face and upper trunk, dry skin, and residual facial telangiectasis. Her scalp hair grew with observable changes: initially brown, straight and smooth, it became rigid, curly and white. She also experienced paronychia. Erlotinib was continued and she was offered the option of laser hair removal. A 53-year-old woman began receiving erlotinib and developed facial hypertrichosis, the typical acneiform eruption and diarrhoea [duration of treatment before reaction onset not stated]. She had no trichomegaly. She responded well to laser hair removal. Hypertrichosis eventually receded following erlotinib discontinuation due to disease progression. Author comment: "The close temporal relationship of the onset of hypertrichosis with the administration of erlotinib, the concomitant presentation of other typical features of EGFR inhibition, and the recession of hypertrichosis after erlotinib discontinuation strongly supports the contributory role of erlotinib in inducing the specific hair changes." Vergou T, et al. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. Journal of the American Academy of Dermatology 63: e56-8, No. 2, Aug 2010 803036193 Greece
0114-9954/10/1318-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 11 Sep 2010 No. 1318
Data Loading...
